Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area

Patrick D.J. Sturm, Inge O. Baas, Marjon J. Clement, Attila Nakeeb, G. Johan A. Offerhaus, Ralph H. Hruban, Henry A. Pitt

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

We observed a clustering of cholangiocarcinoma in a part of West Virginia. We analyzed the frequency and type of alterations in the p53 tumor- suppressor gene and the K-ras oncogene to determine whether cholangiocarcinomas from this high-incidence area differ from other cholangiocarcinomas at the molecular level. We studied 12 carcinomas of patients from the high-incidence area (West Virginia group), and 15 carcinomas of patients from nearby states (non-West Virginia group). Over- expression of the p53 gene product, accompanying most mutations in the p53 gene, was determined by immunohistochemistry. p53 sequence analysis of exons 5, 6, 7, and 8 of the p53-immunohistochemical-positive carcinomas was also performed. K-ras codon 12 mutations were detected by the polymerase chain reaction and allele-specific oligonucleotide hybridization. Significantly more cholangiocarcinomas from the West Virginia group were p53- immunohistochemical-positive than from the non-West Virginia group (67% vs. 20%; p<0.05). p53 mutations did not differ in the 2 groups in respect to site or specific type. No differences were found between the 2 groups regarding K- ras mutations (17% vs. 27%). Although the higher frequency of p53- immunohistochemical positivity in the West Virginia group may reflect a different etiology of these cholangiocarcinomas, explaining the high incidence in this area, results of p53 sequence analysis were not different in the West Virginia group. The high incidence may be explained by difference in carcinogenic dose or a different etiology not reflected in p53 or K-ras alterations.

Original languageEnglish (US)
Pages (from-to)695-698
Number of pages4
JournalInternational Journal of Cancer
Volume78
Issue number6
DOIs
StatePublished - Dec 2 1998

Fingerprint

Klatskin Tumor
ras Genes
Cholangiocarcinoma
Tumor Suppressor Genes
Incidence
Mutation
p53 Genes
Carcinoma
Sequence Analysis
Codon
Oligonucleotides
Cluster Analysis
Exons
Immunohistochemistry
Alleles
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. / Sturm, Patrick D.J.; Baas, Inge O.; Clement, Marjon J.; Nakeeb, Attila; Offerhaus, G. Johan A.; Hruban, Ralph H.; Pitt, Henry A.

In: International Journal of Cancer, Vol. 78, No. 6, 02.12.1998, p. 695-698.

Research output: Contribution to journalArticle

Sturm, Patrick D.J. ; Baas, Inge O. ; Clement, Marjon J. ; Nakeeb, Attila ; Offerhaus, G. Johan A. ; Hruban, Ralph H. ; Pitt, Henry A. / Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. In: International Journal of Cancer. 1998 ; Vol. 78, No. 6. pp. 695-698.
@article{1041806c47ab4090832cd9423de77de5,
title = "Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area",
abstract = "We observed a clustering of cholangiocarcinoma in a part of West Virginia. We analyzed the frequency and type of alterations in the p53 tumor- suppressor gene and the K-ras oncogene to determine whether cholangiocarcinomas from this high-incidence area differ from other cholangiocarcinomas at the molecular level. We studied 12 carcinomas of patients from the high-incidence area (West Virginia group), and 15 carcinomas of patients from nearby states (non-West Virginia group). Over- expression of the p53 gene product, accompanying most mutations in the p53 gene, was determined by immunohistochemistry. p53 sequence analysis of exons 5, 6, 7, and 8 of the p53-immunohistochemical-positive carcinomas was also performed. K-ras codon 12 mutations were detected by the polymerase chain reaction and allele-specific oligonucleotide hybridization. Significantly more cholangiocarcinomas from the West Virginia group were p53- immunohistochemical-positive than from the non-West Virginia group (67{\%} vs. 20{\%}; p<0.05). p53 mutations did not differ in the 2 groups in respect to site or specific type. No differences were found between the 2 groups regarding K- ras mutations (17{\%} vs. 27{\%}). Although the higher frequency of p53- immunohistochemical positivity in the West Virginia group may reflect a different etiology of these cholangiocarcinomas, explaining the high incidence in this area, results of p53 sequence analysis were not different in the West Virginia group. The high incidence may be explained by difference in carcinogenic dose or a different etiology not reflected in p53 or K-ras alterations.",
author = "Sturm, {Patrick D.J.} and Baas, {Inge O.} and Clement, {Marjon J.} and Attila Nakeeb and Offerhaus, {G. Johan A.} and Hruban, {Ralph H.} and Pitt, {Henry A.}",
year = "1998",
month = "12",
day = "2",
doi = "10.1002/(SICI)1097-0215(19981209)78:6<695::AID-IJC5>3.0.CO;2-8",
language = "English (US)",
volume = "78",
pages = "695--698",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area

AU - Sturm, Patrick D.J.

AU - Baas, Inge O.

AU - Clement, Marjon J.

AU - Nakeeb, Attila

AU - Offerhaus, G. Johan A.

AU - Hruban, Ralph H.

AU - Pitt, Henry A.

PY - 1998/12/2

Y1 - 1998/12/2

N2 - We observed a clustering of cholangiocarcinoma in a part of West Virginia. We analyzed the frequency and type of alterations in the p53 tumor- suppressor gene and the K-ras oncogene to determine whether cholangiocarcinomas from this high-incidence area differ from other cholangiocarcinomas at the molecular level. We studied 12 carcinomas of patients from the high-incidence area (West Virginia group), and 15 carcinomas of patients from nearby states (non-West Virginia group). Over- expression of the p53 gene product, accompanying most mutations in the p53 gene, was determined by immunohistochemistry. p53 sequence analysis of exons 5, 6, 7, and 8 of the p53-immunohistochemical-positive carcinomas was also performed. K-ras codon 12 mutations were detected by the polymerase chain reaction and allele-specific oligonucleotide hybridization. Significantly more cholangiocarcinomas from the West Virginia group were p53- immunohistochemical-positive than from the non-West Virginia group (67% vs. 20%; p<0.05). p53 mutations did not differ in the 2 groups in respect to site or specific type. No differences were found between the 2 groups regarding K- ras mutations (17% vs. 27%). Although the higher frequency of p53- immunohistochemical positivity in the West Virginia group may reflect a different etiology of these cholangiocarcinomas, explaining the high incidence in this area, results of p53 sequence analysis were not different in the West Virginia group. The high incidence may be explained by difference in carcinogenic dose or a different etiology not reflected in p53 or K-ras alterations.

AB - We observed a clustering of cholangiocarcinoma in a part of West Virginia. We analyzed the frequency and type of alterations in the p53 tumor- suppressor gene and the K-ras oncogene to determine whether cholangiocarcinomas from this high-incidence area differ from other cholangiocarcinomas at the molecular level. We studied 12 carcinomas of patients from the high-incidence area (West Virginia group), and 15 carcinomas of patients from nearby states (non-West Virginia group). Over- expression of the p53 gene product, accompanying most mutations in the p53 gene, was determined by immunohistochemistry. p53 sequence analysis of exons 5, 6, 7, and 8 of the p53-immunohistochemical-positive carcinomas was also performed. K-ras codon 12 mutations were detected by the polymerase chain reaction and allele-specific oligonucleotide hybridization. Significantly more cholangiocarcinomas from the West Virginia group were p53- immunohistochemical-positive than from the non-West Virginia group (67% vs. 20%; p<0.05). p53 mutations did not differ in the 2 groups in respect to site or specific type. No differences were found between the 2 groups regarding K- ras mutations (17% vs. 27%). Although the higher frequency of p53- immunohistochemical positivity in the West Virginia group may reflect a different etiology of these cholangiocarcinomas, explaining the high incidence in this area, results of p53 sequence analysis were not different in the West Virginia group. The high incidence may be explained by difference in carcinogenic dose or a different etiology not reflected in p53 or K-ras alterations.

UR - http://www.scopus.com/inward/record.url?scp=0031796826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031796826&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19981209)78:6<695::AID-IJC5>3.0.CO;2-8

DO - 10.1002/(SICI)1097-0215(19981209)78:6<695::AID-IJC5>3.0.CO;2-8

M3 - Article

C2 - 9833761

AN - SCOPUS:0031796826

VL - 78

SP - 695

EP - 698

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -